TP53 and metastatic neoplasm: On both UVA and MVA, TP53 mutations, CDKN2A deletion, PTEN deletion, and MYC amplification were prognostic for poor OS in patients with non-metastatic disease, but mut31 was not (Figure 5A, 5B).